Hexarelin, also known as examorelin, is a synthetic analog of ghrelin. Ghrelin, a naturally occurring hormone produced by the stomach, binds with the growth hormone secretagogue receptor (GHS-R1a) in the hippocampus that stimulates growth hormone release. Further, it is involved in the regulation of body weight and protection of cardiomyocytes.

Hexarelin is composed of six amino acids and is closely related to GHRP-6. A team of researchers at Tulane medical school first synthesized it in 1989 in an attempt to develop a growth hormone that had no effect on insulin, glucagon and sex hormone. They found that this synthetic peptide didn’t cause desensitization and had a longer half-life. Since its discovery, it gained the attention of researchers for its cardioprotective effects. On our website, hexarelin for sale is available for educational and research purposes.

From Pubchem

IUPAC Name: L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide
Synonyms: Examorelin, Examorelin [INN]
Molecular Formula: C47H58N12O6
Molecular Weight: 887.0 g/mol
Sequence: HXAWFK
CAD Number: 140703-51-1
PubChem CID: 6918297

1. Hexarelin and Weight Loss

As growth hormone influences metabolism and fat utilization, hexarelin might have an effect on weight loss. In one study, the effect of hexarelin on weight loss was examined in nonobese insulin-resistant MKR mice and their wild-type counterparts (FVB mice) over a period of 12 days. Researchers found that hexarelin treatment significantly improved glucose tolerance and reduced plasma and liver triglycerides in insulin-resistant mice.

Further, it was suggested that the enhanced metabolic effect might be due to the increased differentiation of adipocytes and improved metabolism of lipids by hexarelin [1]. This peptide might have the potential to treat lipid disorders associated with metabolic syndrome.

2. Hexarelin and Heart Health:

Research shows that hexarelin exerts beneficial effects on cardiovascular health, including prevention of heart attack and remodeling. In one study, hexarelin, either alone or in combination with a GHS-R antagonist, was administered to spontaneously hypertensive rats from age 5 weeks to 16 weeks. The results found that hexarelin reduced cardiac fibrosis by decreasing the deposition of myocardial collagen and hydroxyproline content. It also reduced the expression of collagen I and III. Further, it alleviated left ventricular hypertrophy, high blood pressure and left ventricular dysfunction. The study found that these effects were mediated by the activation of GHS-R receptor, as its inhibitor nullified the impact of hexarelin [2].

Another study assessed the cardioprotective effect of hexarelin on rats. The researchers labelled the rat cardiac membrane with radioactive hexarelin. They isolated a binding protein that was found to be similar to CD36, a protein expressed in cardiomyocytes and endothelial cells. Activation of CD36 by hexarelin resulted in increased coronary perfusion pressure in a dose-dependent manner. The effect was absent in mice that lack binding protein, suggesting that CD36 might be involved in causing coronary vasospasm in atherosclerosis and hypercholesterolemia [3].

Furthermore, one more study was conducted to explore the mechanisms involved in the cardioprotective effect of hexarelin. Heart failure caused by myocardial infarction was induced by permanent ligation of the coronary artery in rats. These rats either received a placebo or 100ug/kg hexarelin twice a day for 30 days. The result found that the treatment group showed improved contractile function, alleviation of oxidative stress, fibrosis and apoptosis and reduced histopathological damages. All these effects were achieved by the up-regulation of eNOS and an increase in serum NO concentrations, indicating eNOS as a potential target for therapy against heart failure [4].

Besides its protective effect on heart cells in myocardial infarction, it can shield the heart from the damaging effect of other disorders as well. A study found that hexarelin counteracted the negative changes in cell contraction, calcium transients, action potential duration, and potassium currents in a mouse model of diabetes. Moreover, it enhanced GHS receptor expression and antiapoptotic signals, indicating its cardioprotective function in diabetic rats [5].

3. Hexarelin and Muscle Preservation

Hexarelin has been studied for its role in the prevention of muscle loss. It stimulates the release of growth hormone that promotes protein synthesis, prevents muscle breakdown and causes cell differentiation and proliferation. Therefore, it’s not a surprise that it can preserve muscle mass.

In one study, cisplatin-induced cachexia (muscle loss) was introduced in rats under study. Rats were either given a placebo (control group) or hexarelin. The results found that the control group experienced mitochondrial dysfunction and muscle atrophy. On the other hand, the group that received the test drug exhibited resistance to muscle loss and strength. Further, it was speculated that improved mitochondrial function and reduced inflammatory processes by hexarelin contributed to this effect [6].

4. Current Status of Hexarelin

Research in animal models shows that it can prevent heart attack and myocardial remodelling. Further, it has the potential to aid weight loss. However, we need more research to confirm these effects on humans. FDA hasn’t yet approved it for clinical use. At Element Sarms, hexarelin purchase is available for educational and research institutions. Only buy hexarelin if you are a licensed researcher.

1. Mosa, R., et al., Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology, 2017. 158(10): p. 3174-3187.
2. Xu, X., et al., Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. American Journal of Physiology-Heart and Circulatory Physiology, 2012. 303(6): p. H703-H711.
3. Bodart, V., et al., CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart. Circulation Research, 2002. 90(8): p. 844-849.
4. Barnes, P., Cardioprotective role of myocardial endothelial nitric oxide synthase and serum nitric oxide induced by hexarelin in rats with myocardial infarction-induced heart failure. 2021: p. 395.
5. Zhang, X., L. Qu, L. Chen, and C. Chen, Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats. Physiological Reports, 2018. 6(4): p. e13612.
6. Sirago, G., et al., Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci Rep, 2017. 7(1): p. 13017.